PCa development and progression are dependent on androgen receptor (AR) signaling, and targeting AR with antiandrogens and androgen deprivation therapy (for example, enzalutamide and abiraterone) is a mainstay of treatment for PCa11–14. Here, AR is linked to posterior cortical atrophy.